Visceral fat volume predicts new-onset type 2 diabetes in patients with chronic hepatitis C

Diabetes Research and Clinical Practice

Volumn 94, Issue 3, 2011, Pages 468-470

  Iwasa, Motoh ^a   Mifuji Moroka, Rumi ^a   Hara, Nagisa ^b   Ishidome, Masumi ^b   Iwata, Kazuko ^b   Sugimoto, Ryosuke ^a   Tanaka, Hideaki ^a   Fujita, Naoki ^a   Kobayashi, Yoshinao ^a   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatitis C; Non alcoholic fatty liver disease; Type 2 diabetes mellitus; Visceral fat

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; VISCERAL FAT AREA;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; RISK FACTORS;

EID: 82955203371     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.09.016     Document Type: Article

References (15)

1. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
2. Mavrogiannaki A., Karamanos B., Manesis E.K., Papatheodoridis G.V., Koskinas J., Archimandritis A.J. Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. J Viral Hepat 2009, 16:430-436.
3. Romero-Gómez M., Fernández-Rodríguez C.M., Andrade R.J., Diago M., Alonso S., Planas R., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008, 48:721-727.
4. Kawamura Y., Arase Y., Ikeda K., Hirakawa M., Hosaka T., Kobayashi M., et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010, 123:951-956.
5. Veldt B.J., Chen W., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
6. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
7. Sharabi Y., Eldad A. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity. Am J Med 2000, 109:171.
8. Sattar N., Scherbakova O., Ford I., O'Reilly D.S., Stanley A., Forrest E., et al. West of Scotland coronary prevention study. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004, 53:2855-2860.
9. Vozarova B., Stefan N., Lindsay R.S., Saremi A., Pratley R.E., Bogardus C., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:1889-1895.
10. Kang Y.H., Min H.K., Son S.M., Kim I.J., Kim Y.K. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract 2007, 77:306-313.
11. Wang Y., Rimm E.B., Stampfer M.J., Willett W.C., Hu F.B. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005, 81:555-563.
12. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 2006, 14:2107-2117.
13. Iwasa M., Iwata K., Kaito M., Ikoma J., Yamamoto M., Takeo M., et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition 2004, 20:368-371.
14. Yamamoto M., Iwasa M., Iwata K., Kaito M., Sugimoto R., Urawa N., et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007, 22:498-503.
15. Kim L.J., Nalls M.A., Eiriksdottir G., Sigurdsson S., Launer L.J., Koster A., et al. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik Study. Obesity (Silver Spring) 2011, 19:1265-1271.